This test analyzes the RECQL4, a gene that is associated with three distinct conditions: Rothmund-Thomson syndrome (RTS), Baller-Gerold syndrome (BGS), and RAPADILINO syndrome. These syndromes are each characterized by a specific presentation, but they have overlapping features, including radial ray defects, skeletal abnormalities, slow growth/short stature, and an increased risk for malignancy.
Genetic testing of this gene may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.
RECQL4-related conditions are diagnosed early in life and are characterized by radial ray defects, skeletal abnormalities, and slow growth and short stature. Three distinct syndromes are associated with RECQL4, including:
Rothmund-Thomson syndrome (RTS)
Characterized by poikiloderma (sparse hair, eyelashes, or eyebrows), small stature, skeletal and dental abnormalities, cataracts, and an increased risk for osteosarcoma
Baller-Gerold syndrome (BGS)
Characterized by coronal craniosynostosis with ocular proptosis and bulging forehead, radial ray defects, aplasia or hypoplasia of the radius, growth restriction, and poikiloderma
An acronym for radial ray defect; patellae hypoplasia or aplasia and cleft or highly arched palate; diarrhea and dislocated joints; limb malformation; nose slender and normal intelligence; characterized by pre- and postnatal growth restriction
All RECQL4-related conditions reported to date have an autosomal recessive inheritance pattern.
The prevalence of RECQL4-related conditions is currently unknown.
Analysis of the RECQL4 gene may be considered in individuals with the following (major findings):
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|